OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 56.84K shares, a 35.56% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 747.77K shares, a 726.65% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.18M shares, a 1543.37% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 55.42K shares, a 23.40% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.41M shares, a 206.55% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 460.74K shares, a 40.48% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 774.10K shares, a 570.52% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 115.45K shares, a 44.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 56.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 2.04M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 747.77K shares 10-Q · filed 2026-05-12 | 2.07M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 1.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 1.41M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 55.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 305.80K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 88.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 295.29K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 90.46K shares 10-Q · filed 2025-05-13 | 242.63K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 71.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 460.74K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 44.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 457.80K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 35.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 634.82K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 308.57K shares 10-Q · filed 2024-05-08 | 980.77K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 68.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 774.10K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 221.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 712.34K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 381.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 551.19K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 101.91K shares 10-Q · filed 2023-05-09 | 194.61K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 6.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 115.45K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 60.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 158.62K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 24.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 177.22K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 22.74K shares 10-Q · filed 2022-05-09 | 222.30K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 50.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 206.54K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 79.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 70.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2021-03-31 | 6.99K shares 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |